This table lists SARS-CoV-2 **Spike monoclonal antibody (mAb) resistance
mutations**. The mAb-resistance mutations shown met one or more of the following
criteria: (1) having a ≥5-fold reduction in susceptibility to a clinical stage
mAb; and/or (2) having a DMS escape fraction ≥0.1.

A
<span style="border-radius:.3rem;background-color:#146aa8;color:white;display:inline-block;padding:0 .4rem;">dark blue cell</span>
indicates a median ≥25-fold reduction in susceptibility; a
<span style="border-radius:.3rem;background-color:#7fcbee;display:inline-block;padding:0 .4rem;">light blue cell</span>
indicates a median 5-25-fold reduction in susceptibility; a
<span style="border-radius:.3rem;background-color:white;border:1px solid black;display:inline-block;padding:0 .4rem;">white cell</span>
indicates a median &lt;5-fold reduction in susceptibility; and a
<span style="border-radius:.3rem;background-color:#f0f0f0;border:1px solid #aaa;display:inline-block;padding:0 .4rem;">gray cell</span>
indicates the absence of susceptibility data.

Cells with a plus (+) symbol indicates that the mutation had a DMS escape
fraction ≥0.1. Mutations with a yellow background represent the consensus for
one or more variants of concern or interest.

The numbers in the “in patient” column indicate the numbers of times the
mutation was selected in vivo during prolonged infection or in a patient
receiving an mAb. The numbers in the “in vitro” column indicate the number of
studies the mutation was reported to be selected during passage in the presence
of an mAb.

The proportions in the "prevalence" column show the mutation prevalence reported
by the Kosakovsky Pond laboratory as of June 2022. Proportions ≥ 1/10,000 are
colored in yellow. A CSV/Excel file is available for downloading which includes
the exact values of median folds and DMS escape scores.

<u>MAb abbreviations</u>:
**BAM**: Bamlanivimab / LY-CoV555 / LY3819253;
**ETE**: Etesevimab / LY-CoV016 / JS016 / CB6;
**CAS**: Casirivimab / REGN10933;
**IMD**: Imdevimab / REGN10987;
**CIL**: Cilgavimab / COV2-2130 / AZD1061;
**TIX**: Tixagevimab / COV2-2196 / AZD8895;
**SOT**: Sotrovimab / Vir-7831 / S309;
**BEB**: Bebtelovimab / LY-CoV1404 / LY3853113;
**REG**: Regdanvimab / CT-P59;
**AMU**: Amubarvimab / BRII-196 / P2C-1f11;
**ROM**: Romlusevimab / BRII-198 / P2B-1G5;
**ADI**: Adintrevimab / ADG20 / ADG-2.
